All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.
Uncontrolled, central registration system, all-case, multicenter, special drug use-results surveillance.
Chronic Myeloid Leukemia
Jul 04, 2022
Jul 15, 2028
99 Years and older (Child, Adult, Older Adult)
Prospective observational study. There is no treatment allocation. Patients prescribed with asciminib are eligible to enroll into this study.